Romark, L.C.

romark.com

Romark, L.C. is a pharmaceutical company committed to the discovery, development and commercialization of innovative small molecules for treating infectious diseases and cancers. Our people share a passion for scientific discovery and a desire to make a difference in the world's health.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

DARWINHEALTH ANNOUNCES SCIENTIFIC COLLABORATION WITH PRELUDE THERAPEUTICS IN ONCOLOGY

Prelude Therapeutics | October 13, 2021

news image

DarwinHealth, Inc. today announced a scientific research collaboration that uses its Biomarker Enrichment Strategies for Assays (BEST platform ) to elucidate novel biomarkers that guide translational trajectories of multiple cancer molecules being developed by Prelude Therapeutics. Under the collaboration, DarwinHealth will use its proprietary, quantitative, systems biology-based algorithms, CLIA-approved technologies, and validated approaches focused on Protein Master Regulator (...

Read More

Pharma Tech

PHARMAJET PARTNER ZYDUS CADILA ANNOUNCES COVID-19 VACCINE EXPANSION PLAN TO MULTIPLE COUNTRIES WITH KOREAN FIRM

PharmaJet | January 05, 2022

news image

PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income...

Read More

Business Insights, PHARMA TECH

SPECIALTY PHARMA EXPERT ADOPTS NAME OF GLOBAL PARENT TO REFLECT BREADTH OF OFFER THAT BRINGS A RARE AND SPECIAL PERSPECTIVE TO THE MARKET

Businesswire | April 26, 2023

news image

Global healthcare and business consulting services provider, Terebellum, has chosen to adopt the name of its global parent, AscellaHealth, to reflect the scale of its operations and breadth of expertise. The business specialises in providing end-to-end solutions to pharmaceutical manufacturers and other industry stakeholders to streamline product commercialisation, improve medication access, reduce costs and enhance patient outcomes for specialty and rare disease patients. ...

Read More

AMARIN ANNOUNCES PLANS TO MAXIMIZE BLOCKBUSTER POTENTIAL OF VASCEPA® IN EUROPE

Amarin spurns | August 05, 2020

news image

Amarin's wild 2020 ride continues. Tuesday, the company said COVID-19 took a bite out of second quarter earnings, and it unveiled plans to launch its fish-oil derivative drug Vascepa in Europe without help from a bigger marketing partner. And that's on top of prepping for federal court this fall, where it will try to salvage Vascepa's key patents. Amarin positioned its European plans as a positive: It did receive multiple proposals from potential partners. But the significant sales o...

Read More
news image

Research

DARWINHEALTH ANNOUNCES SCIENTIFIC COLLABORATION WITH PRELUDE THERAPEUTICS IN ONCOLOGY

Prelude Therapeutics | October 13, 2021

DarwinHealth, Inc. today announced a scientific research collaboration that uses its Biomarker Enrichment Strategies for Assays (BEST platform ) to elucidate novel biomarkers that guide translational trajectories of multiple cancer molecules being developed by Prelude Therapeutics. Under the collaboration, DarwinHealth will use its proprietary, quantitative, systems biology-based algorithms, CLIA-approved technologies, and validated approaches focused on Protein Master Regulator (...

Read More
news image

Pharma Tech

PHARMAJET PARTNER ZYDUS CADILA ANNOUNCES COVID-19 VACCINE EXPANSION PLAN TO MULTIPLE COUNTRIES WITH KOREAN FIRM

PharmaJet | January 05, 2022

PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income...

Read More
news image

Business Insights, PHARMA TECH

SPECIALTY PHARMA EXPERT ADOPTS NAME OF GLOBAL PARENT TO REFLECT BREADTH OF OFFER THAT BRINGS A RARE AND SPECIAL PERSPECTIVE TO THE MARKET

Businesswire | April 26, 2023

Global healthcare and business consulting services provider, Terebellum, has chosen to adopt the name of its global parent, AscellaHealth, to reflect the scale of its operations and breadth of expertise. The business specialises in providing end-to-end solutions to pharmaceutical manufacturers and other industry stakeholders to streamline product commercialisation, improve medication access, reduce costs and enhance patient outcomes for specialty and rare disease patients. ...

Read More
news image

AMARIN ANNOUNCES PLANS TO MAXIMIZE BLOCKBUSTER POTENTIAL OF VASCEPA® IN EUROPE

Amarin spurns | August 05, 2020

Amarin's wild 2020 ride continues. Tuesday, the company said COVID-19 took a bite out of second quarter earnings, and it unveiled plans to launch its fish-oil derivative drug Vascepa in Europe without help from a bigger marketing partner. And that's on top of prepping for federal court this fall, where it will try to salvage Vascepa's key patents. Amarin positioned its European plans as a positive: It did receive multiple proposals from potential partners. But the significant sales o...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us